VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Adelstein on Adjuvant Therapy for Oral Cancer

David Adelstein, MD
Published: Tuesday, Mar 08, 2016



David Adelstein, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses adjuvant therapy options for patients with oral cancer.

Chemotherapy is a preferred treatment option for patients with high-risk disease, Adelstein explains. Evidence suggests that the use of high-dose cisplatin benefits select patients in terms of locoregional control and survival. However, there is less evidence showing that weekly treatment with cisplatin is as effective.

No data suggest that carboplatin, cetuximab, or taxane-based therapies in the adjuvant setting have a role in these patients. Radiation therapy has also shown to be a reasonable approach in patients who are unable to tolerate cisplatin.

<<< View more from the 2016 Multidisciplinary Head and Neck Cancer Symposium



David Adelstein, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses adjuvant therapy options for patients with oral cancer.

Chemotherapy is a preferred treatment option for patients with high-risk disease, Adelstein explains. Evidence suggests that the use of high-dose cisplatin benefits select patients in terms of locoregional control and survival. However, there is less evidence showing that weekly treatment with cisplatin is as effective.

No data suggest that carboplatin, cetuximab, or taxane-based therapies in the adjuvant setting have a role in these patients. Radiation therapy has also shown to be a reasonable approach in patients who are unable to tolerate cisplatin.

<<< View more from the 2016 Multidisciplinary Head and Neck Cancer Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x